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Although the glucocorticoids delay the progression of Duchenne muscular dystro-
phy (DMD) their mechanism of action is unknown. In our previous studies we dem-
onstrated that in the mdx mice, an animal model of DMD, besides the muscle degen-
eration, serious damages of the blood-brain barrier (BBB) occur taking to enhanced 
vessels permeability and brain edema (1). Moreover, we observed that the mdx mice 
after α–methyl-prednisolone (PDN) treatment ameloriated the histopathological pro-
fi les and the excitation-contraction of the myofi bers (2).
In this study, we evaluated the eff ects of the PDN on the BBB of the mdx mice, by 
estimating the immunocytochemical and biochemical expression of endothelial ZO-1 
and occludin, pericyte desmin, and glial GFAP and short dystrophin isoform Dp 71 
proteins, used as BBB markers. In addition, we analyzed the expression of dystro-
phin associate proteins (DAPs) aquaporin-4 (AQP4) and α-β dystroglycan in parallel 
in both brain and muscles of PDN treated mdx as well as in control mice. Results 
showed in mdx PDN treated mice a signifi cant increase of the mRNA and protein 
content of all the glial, pericyte and endothelial proteins as compared to untreated 
mdx. Moreover, by immunoprecipitation we demonstrated that the BBB alteration 
in the mdx mice were coupled with enhanced occludin and AQP4 phosphorylation 
degree which, instead, was reduced after PDN treatment. Finally we observed that 
AQP4 and α-β dystroglycan complex increases its mRNA and protein content in both 
PDN mdx brain and muscle fi bers, compared with mdx mice where the perivascu-
lar glial membranes and the myofi bers showed a light staining after immunoﬂ uo-
rescence analysis . These data indicate that the PDN restores the BBB damages in 
the mdx mice by inducing in the glial cell the expression of GFAP, AQP4 and Dp71 
proteins and in the pericytes and endothelial cells, of the desmin and ZO-1 proteins, 
which are defi cient in the distrophic mice. Moreover, the reduction in the AQP4 and 
occludin phosphorylation degree coupled with their ankoring to glial and endothelial 
membranes in the PDN mdx mice suggests that the glial and endothelial cells may 
be a cellular target of the drug. Finally, the enhanced expression of DAPs AQP4 and 
α-β dystroglycan in both brain and myofi bers of PDN treated mdx mice compared to 
untreated mdx ones suggest the PDN might ameliorate the brain vessels and muscles 
functions of the dystrophic mice by a restoring a correct links between DAPs proteins 
and the extracellular matrix.
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